CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in...
Phase 2
Salt Lake City, Utah, United States and 31 other locations
versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...
Phase 3
Salt Lake City, Utah, United States and 59 other locations
1b/2, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple...
Phase 1, Phase 2
Salt Lake City, Utah, United States and 12 other locations
doses) of the study medicine (elranatamab) in participants with multiple myeloma that has come back after responding to treatment o ...
Phase 2
Salt Lake City, Utah, United States and 42 other locations
The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in participants with relapsed or refractory multiple myeloma...
Phase 2
Salt Lake City, Utah, United States and 46 other locations
of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longe...
Phase 1
Salt Lake City, Utah, United States and 17 other locations
combination with DEX for Relapsed Refractory Multiple Myeloma (RRMM), CC-220 in combination with DEX and BTZ, and CC-220 in combin ...
Phase 1, Phase 2
Salt Lake City, Utah, United States and 88 other locations
A Phase II study of anitocabtagene-autoleucel (formerly CART-ddBCMA) for patients with relapsed or refractory multiple myeloma. Ani...
Phase 2
Salt Lake City, Utah, United States and 19 other locations
A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexa...
Phase 3
Salt Lake City, Utah, United States and 180 other locations
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose o...
Phase 1
Salt Lake City, Utah, United States and 48 other locations
Clinical trials
Research sites
Resources
Legal